Literature DB >> 19148300

Molecularly targeted therapies for malignant gliomas.

Andreas A Argyriou1, Haralabos P Kalofonos.   

Abstract

This review critically evaluates current knowledge of molecularly targeted therapies of malignant gliomas.Various molecularly targeted single-agent therapies, including targeted therapies of growth and survival, have been evaluated in clinical trials but have failed to demonstrate a significant survival benefit compared with standard treatment regimens. The efficacy of multitargeted kinase inhibitors or combinations of single-targeted kinase inhibitors is a promising strategy, but requires additional clinical evaluation before definitive conclusions can be made. Important areas for further research include the assessment of serum or tissue biomarkers, the elucidation of prognostic molecular markers, and the determination of whether the mechanism of action of a drug is appropriate to the genetic alterations observed within individual tumors.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19148300      PMCID： PMC2646824          DOI： 10.2119/molmed.2008.00123

Source DB:  PubMed          Journal:  Mol Med        ISSN： 1076-1551            Impact factor:   6.354


  60 in total

1.  Targeted imaging of human endothelial-specific marker in a model of adoptive cell transfer.

Authors:  Hye Won Kang; Denise Torres; Lawrence Wald; Ralph Weissleder; Alexei A Bogdanov
Journal:  Lab Invest       Date:  2006-06       Impact factor: 5.662

2.  Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.

Authors:  Sunil Krishnan; Paul D Brown; Karla V Ballman; John B Fiveash; Joon H Uhm; Caterina Giannini; Kurt A Jaeckle; Francois J Geoffroy; L Burt Nabors; Jan C Buckner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-04-19       Impact factor: 7.038

3.  Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors.

Authors:  Zbigniew Wygoda; Dorota Kula; Grazyna Bierzyńska-Macyszyn; Dawid Larysz; Michał Jarzab; Paweł Właszczuk; Piotr Bazowski; Maciej Wojtacha; Adam Rudnik; Tomasz Stepień; Wojciech Kaspera; Aleksandra Etmańska; Krzysztof Składowski; Rafał Tarnawski; Danuta Kokocińska; Barbara Jarzab
Journal:  Hybridoma (Larchmt)       Date:  2006-06

4.  Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.

Authors:  David A Reardon; Merrill J Egorin; Jennifer A Quinn; Jeremy N Rich; Jeremy N Rich; Sridharan Gururangan; Idharan Gururangan; James J Vredenburgh; Annick Desjardins; Sith Sathornsumetee; James M Provenzale; James E Herndon; Jeannette M Dowell; Michael A Badruddoja; Roger E McLendon; Theodore F Lagattuta; Kimberly P Kicielinski; Gregor Dresemann; John H Sampson; Allan H Friedman; August J Salvado; Henry S Friedman
Journal:  J Clin Oncol       Date:  2005-12-20       Impact factor: 44.544

5.  Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

Authors:  Timothy F Cloughesy; Patrick Y Wen; H Ian Robins; Susan M Chang; Morris D Groves; Karen L Fink; Larry Junck; David Schiff; Lauren Abrey; Mark R Gilbert; Frank Lieberman; John Kuhn; Lisa M DeAngelis; Minesh Mehta; Jeff J Raizer; W K Alfred Yung; Ken Aldape; John Wright; Kathleen R Lamborn; Michael D Prados
Journal:  J Clin Oncol       Date:  2006-08-01       Impact factor: 44.544

6.  Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

Authors:  Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Patricia L Dahia; Yanfeng Wang; Bin Peng; Lauren E Abrey; Jeffrey Raizer; Timothy F Cloughesy; Karen Fink; Mark Gilbert; Susan Chang; Larry Junck; David Schiff; Frank Lieberman; Howard A Fine; Minesh Mehta; H Ian Robins; Lisa M DeAngelis; Morris D Groves; Vinay K Puduvalli; Victor Levin; Charles Conrad; Elizabeth A Maher; Kenneth Aldape; Michael Hayes; Laurie Letvak; Merrill J Egorin; Renaud Capdeville; Richard Kaplan; Anthony J Murgo; Charles Stiles; Michael D Prados
Journal:  Clin Cancer Res       Date:  2006-08-15       Impact factor: 12.531

7.  Prognostic impact of molecular markers in a series of 220 primary glioblastomas.

Authors:  Caroline Houillier; Julie Lejeune; Alexandra Benouaich-Amiel; Florence Laigle-Donadey; Emmanuelle Criniere; Karima Mokhtari; Joelle Thillet; Jean-Yves Delattre; Khe Hoang-Xuan; Marc Sanson
Journal:  Cancer       Date:  2006-05-15       Impact factor: 6.860

8.  Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.

Authors:  Michael D Prados; Kathleen R Lamborn; Susan Chang; Eric Burton; Nicholas Butowski; Mary Malec; Ami Kapadia; Jane Rabbitt; Margaretta S Page; Ann Fedoroff; Dong Xie; Sean K Kelley
Journal:  Neuro Oncol       Date:  2006-01       Impact factor: 12.300

Review 9.  Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.

Authors:  Marc-Eric Halatsch; Ursula Schmidt; Julianne Behnke-Mursch; Andreas Unterberg; Christian Rainer Wirtz
Journal:  Cancer Treat Rev       Date:  2006-02-20       Impact factor: 12.111

Review 10.  Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.

Authors:  David A Reardon; Patrick Y Wen
Journal:  Oncologist       Date:  2006-02
View more
  15 in total

1.  Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells.

Authors:  Christopher M Furcht; Janine M Buonato; Nicolas Skuli; Lijoy K Mathew; Andrés R Muñoz Rojas; M Celeste Simon; Matthew J Lazzara
Journal:  J Cell Sci       Date:  2014-06-20       Impact factor: 5.285

2.  Long non-coding RNA Fer-1-like family member 4 is overexpressed in human glioblastoma and regulates the tumorigenicity of glioma cells.

Authors:  Feng Ding; Hongtu Tang; Dekang Nie; Liang Xia
Journal:  Oncol Lett       Date:  2017-06-16       Impact factor: 2.967

3.  Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation.

Authors:  Heike Peterziel; Julia Müller; Andreas Danner; Sebastian Barbus; Hai-Kun Liu; Bernhard Radlwimmer; Torsten Pietsch; Peter Lichter; Günther Schütz; Jochen Hess; Peter Angel
Journal:  Neuro Oncol       Date:  2012-03-06       Impact factor: 12.300

Review 4.  Experimental approaches for the treatment of malignant gliomas.

Authors:  Leopold Arko; Igor Katsyv; Grace E Park; William Patrick Luan; John K Park
Journal:  Pharmacol Ther       Date:  2010-06-08       Impact factor: 12.310

Review 5.  Signaling in malignant astrocytomas: role of neural stem cells and its therapeutic implications.

Authors:  Sheila R Alcantara Llaguno; Jian Chen; Luis F Parada
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

6.  Frontiers in Suicide Gene Therapy of Cancer.

Authors:  Marek Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2012-10-22

7.  Endothelial differentiation of adipose tissue-derived mesenchymal stromal cells in glioma tumors: implications for cell-based therapy.

Authors:  Juli R Bagó; Maria Alieva; Carolina Soler; Núria Rubio; Jerónimo Blanco
Journal:  Mol Ther       Date:  2013-06-13       Impact factor: 11.454

8.  Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas.

Authors:  C Ciceroni; M Bonelli; E Mastrantoni; C Niccolini; M Laurenza; L M Larocca; R Pallini; A Traficante; P Spinsanti; L Ricci-Vitiani; A Arcella; R De Maria; F Nicoletti; G Battaglia; D Melchiorri
Journal:  Cell Death Differ       Date:  2012-11-23       Impact factor: 15.828

9.  Glioblastoma therapy with cytotoxic mesenchymal stromal cells optimized by bioluminescence imaging of tumor and therapeutic cell response.

Authors:  Maria Alieva; Juli R Bagó; Elisabet Aguilar; Carolina Soler-Botija; Olaia F Vila; Joan Molet; Sanjiv S Gambhir; Nuria Rubio; Jerónimo Blanco
Journal:  PLoS One       Date:  2012-04-17       Impact factor: 3.240

10.  Amlexanox, a selective inhibitor of IKBKE, generates anti-tumoral effects by disrupting the Hippo pathway in human glioblastoma cell lines.

Authors:  Yang Liu; Jie Lu; Zhimeng Zhang; Lin Zhu; Shicai Dong; Gaochao Guo; Ruohong Li; Yang Nan; Kai Yu; Yue Zhong; Qiang Huang
Journal:  Cell Death Dis       Date:  2017-08-31       Impact factor: 8.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.